190 related articles for article (PubMed ID: 32735623)
1. Second-line treatment in advanced gastric cancer: Data from the Spanish AGAMENON registry.
Cotes Sanchís A; Gallego J; Hernandez R; Arrazubi V; Custodio A; Cano JM; Aguado G; Macias I; Lopez C; López F; Visa L; Garrido M; Martínez Lago N; Fernández Montes A; Limón ML; Azkárate A; Pimentel P; Reguera P; Ramchandani A; Cacho JD; Martín Carnicero A; Granja M; Martín Richard M; Hernández Pérez C; Hurtado A; Serra O; Buxo E; Vidal Tocino R; Jimenez-Fonseca P; Carmona-Bayonas A
PLoS One; 2020; 15(7):e0235848. PubMed ID: 32735623
[TBL] [Abstract][Full Text] [Related]
2. Does HER2 status influence in the benefit of ramucirumab and paclitaxel as second line treatment of advanced gastro-esophageal adenocarcinoma? Data from the AGAMENON-SEOM registry.
Valcarcel S; Gallego J; Jimenez-Fonseca P; Diez M; de Castro EM; Hernandez R; Arrazubi V; Custodio A; Cano JM; Montes AF; Macias I; Visa L; Calvo A; Tocino RV; Lago NM; Limón ML; Granja M; Gil M; Pimentel P; Macia-Rivas L; Pérez CH; Mangas M; Carnicero AM; Cerdà P; Gonzalez LG; Navalon FG; Rambla MDM; Richard MM; Carmona-Bayonas A
J Cancer Res Clin Oncol; 2023 Jul; 149(7):4077-4089. PubMed ID: 36042046
[TBL] [Abstract][Full Text] [Related]
3. Effect of First-line S-1 Plus Oxaliplatin With or Without Ramucirumab Followed by Paclitaxel Plus Ramucirumab on Advanced Gastric Cancer in East Asia: The Phase 2 RAINSTORM Randomized Clinical Trial.
Yoshikawa T; Muro K; Shitara K; Oh DY; Kang YK; Chung HC; Kudo T; Chin K; Kadowaki S; Hamamoto Y; Hironaka S; Yoshida K; Yen CJ; Omuro Y; Bai LY; Maeda K; Ozeki A; Yoshikawa R; Kitagawa Y
JAMA Netw Open; 2019 Aug; 2(8):e198243. PubMed ID: 31373648
[TBL] [Abstract][Full Text] [Related]
4. Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial.
Di Bartolomeo M; Niger M; Morano F; Corallo S; Antista M; Tamberi S; Lonardi S; Di Donato S; Berardi R; Scartozzi M; Cardellino GG; Di Costanzo F; Rimassa L; Luporini AG; Longarini R; Zaniboni A; Bertolini A; Tomasello G; Pinotti G; Scagliotti G; Tortora G; Bonetti A; Spallanzani A; Frassineti GL; Tassinari D; Giuliani F; Cinieri S; Maiello E; Verusio C; Bracarda S; Catalano V; Basso M; Ciuffreda L; De Vita F; Parra HS; Fornaro L; Caporale M; de Braud F; Pietrantonio F
BMC Cancer; 2019 Mar; 19(1):283. PubMed ID: 30922323
[TBL] [Abstract][Full Text] [Related]
5. Docetaxel monotherapy as a second-line treatment after failure of fluoropyrimidine and platinum in advanced gastric cancer: experience of 154 patients with prognostic factor analysis.
Jo JC; Lee JL; Ryu MH; Sym SJ; Lee SS; Chang HM; Kim TW; Lee JS; Kang YK
Jpn J Clin Oncol; 2007 Dec; 37(12):936-41. PubMed ID: 18211985
[TBL] [Abstract][Full Text] [Related]
6. A prospective observational study on the optimal maintenance strategy in HER2-positive advanced gastric cancer treated with trastuzumab-based therapy.
Li Q; Lv M; Jiang H; Wang Y; Yu S; Li W; Yu Y; Liu T
J Cancer Res Clin Oncol; 2020 Jan; 146(1):287-295. PubMed ID: 31667572
[TBL] [Abstract][Full Text] [Related]
7. Optimal duration of first-line chemotherapy for advanced gastric cancer: data from the AGAMENON registry.
Viúdez A; Carmona-Bayonas A; Gallego J; Lacalle A; Hernández R; Cano JM; Macías I; Custodio A; Martínez de Castro E; Sánchez A; Iglesia L; Reguera P; Visa L; Azkarate A; Sánchez-Cánovas M; Mangas M; Limón ML; Martínez-Torrón A; Asensio E; Ramchandani A; Martín-Carnicero A; Hurtado A; Cerdà P; Garrido M; Sánchez-Bayonas R; Serrano R; Jiménez-Fonseca P;
Clin Transl Oncol; 2020 May; 22(5):734-750. PubMed ID: 31385226
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety findings from DREAM: a phase III study of DHP107 (oral paclitaxel) versus i.v. paclitaxel in patients with advanced gastric cancer after failure of first-line chemotherapy.
Kang YK; Ryu MH; Park SH; Kim JG; Kim JW; Cho SH; Park YI; Park SR; Rha SY; Kang MJ; Cho JY; Kang SY; Roh SY; Ryoo BY; Nam BH; Jo YW; Yoon KE; Oh SC
Ann Oncol; 2018 May; 29(5):1220-1226. PubMed ID: 29438463
[TBL] [Abstract][Full Text] [Related]
9. Clinical Implications of Decreased Computed Tomography Value after Ramucirumab in Advanced Gastric Cancer.
Izawa N; Sunakawa Y; Doi A; Arai H; Horie Y; Hirakawa M; Mizukami T; Ogura T; Tsuda T; Nakajima TE
Oncology; 2019; 97(2):94-101. PubMed ID: 31195391
[TBL] [Abstract][Full Text] [Related]
10. Phase II clinical trial of second-line weekly paclitaxel plus trastuzumab for patients with HER2-positive metastatic gastric cancer.
Horita Y; Nishino M; Sugimoto S; Kida A; Mizukami A; Yano M; Arihara F; Matsuda K; Matsuda M; Sakai A
Anticancer Drugs; 2019 Jan; 30(1):98-104. PubMed ID: 30124494
[TBL] [Abstract][Full Text] [Related]
11. Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with Trastuzumab.
Díaz-Serrano A; Angulo B; Dominguez C; Pazo-Cid R; Salud A; Jiménez-Fonseca P; Leon A; Galan MC; Alsina M; Rivera F; Plaza JC; Paz-Ares L; Lopez-Rios F; Gómez-Martín C
Oncologist; 2018 Sep; 23(9):1092-1102. PubMed ID: 29700210
[TBL] [Abstract][Full Text] [Related]
12. Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study.
Parisi A; Cortellini A; Roberto M; Venditti O; Santini D; Dell'Aquila E; Stellato M; Marchetti P; Occhipinti MA; Zoratto F; Mazzuca F; Tinari N; De Tursi M; Iezzi L; Natoli C; Ratti M; Pizzo C; Ghidini M; Porzio G; Ficorella C; Cannita K
J Cancer Res Clin Oncol; 2019 Sep; 145(9):2365-2373. PubMed ID: 31280347
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancer.
Bando H; Shimodaira H; Fujitani K; Takashima A; Yamaguchi K; Nakayama N; Takahashi T; Oki E; Azuma M; Nishina T; Hironaka S; Komatsu Y; Shitara K
Eur J Cancer; 2018 Mar; 91():86-91. PubMed ID: 29353164
[TBL] [Abstract][Full Text] [Related]
14. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.
Wilke H; Muro K; Van Cutsem E; Oh SC; Bodoky G; Shimada Y; Hironaka S; Sugimoto N; Lipatov O; Kim TY; Cunningham D; Rougier P; Komatsu Y; Ajani J; Emig M; Carlesi R; Ferry D; Chandrawansa K; Schwartz JD; Ohtsu A;
Lancet Oncol; 2014 Oct; 15(11):1224-35. PubMed ID: 25240821
[TBL] [Abstract][Full Text] [Related]
15. Retention of platinum sensitivity till late stages of tumour progression may imply improved prognosis of oesophageal and gastric cancers.
Hingorani M; Dixit S; Roy R; Maraveyas A
Oncol Res Treat; 2015; 38(1-2):28-34. PubMed ID: 25634795
[TBL] [Abstract][Full Text] [Related]
16. Progression-free survival and post-progression survival in patients with advanced gastric cancer treated with first-line chemotherapy.
Shitara K; Matsuo K; Muro K; Doi T; Ohtsu A
J Cancer Res Clin Oncol; 2013 Aug; 139(8):1383-9. PubMed ID: 23708301
[TBL] [Abstract][Full Text] [Related]
17. The role of ramucirumab plus paclitaxel as second-line therapy after failure of nivolumab plus doublet chemotherapy in patients with advanced gastric cancer.
Jeon Y; Lim SH; Lee J; Kang WK; Jang JY; Jeong SY; Choi D; Kim ST
J Gastrointest Oncol; 2023 Dec; 14(6):2346-2353. PubMed ID: 38196521
[TBL] [Abstract][Full Text] [Related]
18. The Impact of Molecular Subtype on Efficacy of Chemotherapy and Checkpoint Inhibition in Advanced Gastric Cancer.
Kubota Y; Kawazoe A; Sasaki A; Mishima S; Sawada K; Nakamura Y; Kotani D; Kuboki Y; Taniguchi H; Kojima T; Doi T; Yoshino T; Ishii G; Kuwata T; Shitara K
Clin Cancer Res; 2020 Jul; 26(14):3784-3790. PubMed ID: 32156744
[TBL] [Abstract][Full Text] [Related]
19. Ramucirumab for the treatment of metastatic gastric or gastroesophageal junction adenocarcinoma following disease progression on first-line platinum- or fluoropyrimidine-containing combination therapy in Japanese patients: a phase 2, open-label study.
Yamaguchi K; Fujitani K; Nagashima F; Omuro Y; Machida N; Nishina T; Koue T; Tsujimoto M; Maeda K; Satoh T
Gastric Cancer; 2018 Nov; 21(6):1041-1049. PubMed ID: 29508095
[TBL] [Abstract][Full Text] [Related]
20. Clinical usefulness of ramucirumab plus paclitaxel for unresectable and recurrent gastric cancer.
Hayase S; Yamada L; Ujiie D; Nirei A; Tada T; Hanayama H; Monma T; Saze Z; Ohki S; Kono K
Fukushima J Med Sci; 2019; 65(1):6-12. PubMed ID: 30996218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
